Newsenselab
Newsenselab GmbH created M-sense, the first prescription migraine app to help sufferers reduce headaches.
Newsenselab GmbH created M-sense, the first prescription migraine app to help sufferers reduce headaches.
Newsenselab GmbH, founded in 2016 and headquartered in Germany, has made waves in the digital health industry with its groundbreaking product M-sense Migraine. This innovative app, dubbed as the first prescription migraine app, is designed to assist individuals in managing and reducing the frequency of headaches. The involvement of leading headache specialists in its development attests to its credibility and effectiveness. The latest investment of €375.00K in a Seed Round by IBB Ventures, Noaber, HTGF | High-Tech Gruenderfonds, and MedTech Entrepreneurs (MTE) at 20 December 2021 underscores the industry's confidence in the company and its potential for growth.
With their focus on digital health, Newsenselab GmbH has positioned itself at the forefront of healthcare innovation, promising significant advancements in the field of migraine management. The app's prescription-based foundation and the recent substantial investment from prominent venture capital firms demonstrate the company's trajectory towards success and its ability to make a significant impact on the health and wellness industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round - Newsenselab (M | €375.00K | 4 |
|
20 Dec 2021 |
| Seed Round - Newsenselab (M | €1.20M | 4 |
|
03 Dec 2019 |
| Venture Round - Newsenselab (M | Unknown | 2 | Think.Health, HTGF | High-Tech Gruenderfonds | 24 Jan 2018 |
| Venture Round - Newsenselab (M | Unknown | - | 28 Nov 2016 |
No recent news or press coverage available for Newsenselab.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
